Invasive pulmonary Aspergillosis in patients with chronic obstructive pulmonary disease: An emerging fungal disease

被引：34

作者：

Ader F. ^{[1
,2
]}

机构：

[1] Department of Infectious Diseases, Croix-Rousse Hospital

[2] Inserm U851, Finovi Centre d'Infectiologie Innate Immunity and Bacterial Pathogenesis, Claude Bernard Lyon 1 University

来源：

Current Infectious Disease Reports | 2010年 / 12卷 / 6期

关键词：

Aspergillus; Chronic obstructive pulmonary disease; Corticosteroids; Invasive pulmonary aspergillosis;

D O I：

10.1007/s11908-010-0132-1

中图分类号：

学科分类号：

摘要：

Invasive pulmonary aspergillosis (IPA) is a necrotizing pneumonia caused by airborne opportunistic fungi of Aspergillus species. Patients with advanced-stage chronic obstructive pulmonary disease (COPD) have emerged to be at risk for IPA as a result of the overall improvement of long-term management of the disease. IPA is among the most severe infectious event that may occur during the course of COPD resulting from profound immune impairment and associated with poor outcome. Many aspects of the development of IPA in COPD patients differ from hematologic patients, explaining various patterns of IPA in an expanded population of immunocompromised patients. Therefore, it is legitimate to focus on the literature-based data available regarding the factors involved in the development of IPA in this setting as well as the use and interpretation of diagnosis criteria, and the treatment options. © 2010 Springer Science+Business Media, LLC.

引用

页码：409 / 416

页数：7

共 62 条

[1]

Perfect J.R., Cox G.M., Lee J.Y., Kauffman C.A., De Repentigny L., Chapman S.W., Morrison V.A., Pappas P., Hiemenz J.W., Stevens D.A., The impact of culture isolation of Aspergillus species: A hospital-based survey of aspergillosis, Clinical Infectious Diseases, 33, 11, pp. 1824-1833, (2001)

[2]

Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., Morrison V.A., Segal B.H., Steinbach W.J., Stevens D.A., Van Burik J.-A., Wingard J.R., Patterson T.F., Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of America, Clinical Infectious Diseases, 46, 3, pp. 327-360, (2008)

[3]

Ader F., Bienvenu A.L., Rammaert B., Nseir S., Management of invasive aspergillosis in patients with COPD: Rational use of voriconazole, Int J COPD, 4, pp. 279-287, (2009)

[4]

Meersseman W., Lagrou K., Maertens J., Van Wijngaerden E., Invasive aspergillosis in the intensive care unit, Clinical Infectious Diseases, 45, 2, pp. 205-216, (2007)

[5]

Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., Fukuchi Y., Jenkins C., Rodriguez-Roisin R., Van Weel C., Zielinski J., Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary, American Journal of Respiratory and Critical Care Medicine, 176, 6, pp. 532-555, (2007)

[6]

Chung K.F., Adcock I.M., Multifaceted mechanisms in COPD: Inflammation, immunity, and tissue repair and destruction, Eur Respir J, 31, pp. 1334-1356, (2008)

[7]

Sethi S., Murphy T.F., Infection in the pathogenesis and course of chronic obstructive pulmonary disease, N Engl J Med, 359, pp. 2355-2365, (2008)

[8]

Patterson T.F., Kirkpatrick W.R., White M., Hiemenz J.W., Wingard J.R., Dupont B., Rinaldi M.G., Stevens D.A., Graybill J.R., Invasive aspergillosis: Disease spectrum, treatment practices, and outcomes, Medicine, 79, 4, pp. 250-260, (2000)

[9]

Lin S.-J., Schranz J., Teutsch S.M., Aspergillosis case-fatality rate: Systematic review of the literature, Clinical Infectious Diseases, 32, 3, pp. 358-366, (2001)

[10]

Thommi G., Bell G., Liu J., Nugent K., Spectrum of invasive pulmonary aspergillosis in immunocompetent patients with chronic obstructive pulmonary disease, South Med J, 84, pp. 828-831, (1991)

← 1 2 3 4 5 6 7 →